Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial

• DOI: 10.1007/s00432-014-1682-7
• Publication Date: 2014-05-09T06:25:47Z
• Authors: Hans-Joachim Schmoll; Burghardt Wittig; Dirk Arnold; Jorge Riera-Knorr...; Dieter Nitsche; Hendrik Kroening; Frank Mayer; Johannes Andel; Reinhard Ziebermayr; Werner Scheithauer
• Keywords: Clinical endpoint; Maintenance therapy

This phase II study evaluated the synthetic DNA-based immunomodulator and Toll-like receptor 9 agonist MGN1703 as maintenance treatment in metastatic colorectal carcinoma (mCRC).